Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma

Inclusion Criteria

• Histologic proof of stage IV malignant melanoma not amenable to surgery; (biopsy can be of locoregional disease in setting of clinically evident stage IV disease, but primary tumor alone will not qualify)
• At most one prior chemotherapy based regimen for metastatic melanoma (no prior taxane-based regimens allowed); note: prior adjuvant non-taxane based chemotherapy and/or adjuvant immunotherapy are allowed; no limit on the number of prior biologic, immunologic or targeted therapies
• Measurable disease defined as at least one lesion whose longest diameter can be accurately measured as >= 2.0 cm with chest x-ray, or as >= 1.0 cm with computed tomography (CT) scan, CT component of a positron emission tomography (PET)/CT, or magnetic resonance imaging (MRI) scan; note: disease that is measurable by physical examination only is not eligible
• Life expectancy >= 4 months
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• Absolute neutrophil count (ANC) >= 1500/mL
• Platelets (PLT) >= 100,000 x 10^9/L
• Hemoglobin (Hgb) >= 9 g/dL (patients may be transfused to meet this requirement)
• Total cholesterol = = 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate = =150 mm Hg systolic and/or 100 mmHg diastolic) despite treatment
• New York Heart Association class II-IV congestive heart failure
• Serious cardiac arrhythmia requiring medication
• Myocardial infarction or unstable angina = 1.5 x ULN
• Severely impaired lung function as defined as spirometry and diffusing capacity of the lung for carbon monoxide (DLCO) that is 50% of the normal predicted value and/or 02 saturation that is 88% or less at rest on room air
• A known history of human immunodeficiency virus (HIV) seropositivity
• Any of the following as this regimen may be harmful to a developing fetus or nursing child:
• Pregnant women
• Nursing women
• Men and women of reproductive potential who are not using effective birth control methods must use highly effective contraception throughout the trail and for 6 months after last study treatment
• Existence of peripheral sensory neuropathy >= grade 2
• History of other malignancy = 25% of their functional bone marrow irradiated are not eligible for this trial
• Active or recent history of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) = = 7 days after discontinuation of such agent
• Positive hepatitis B antigen (HBsAg) or hepatitis C serology (HCV) tests
• Planned immunization with attenuated live vaccines =< 7 days prior to registration or during study period; note: close contact with those who have received attenuated live vaccines should be avoided during treatment with everolimus; examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Guérin (BCG), yellow fever, varicella and TY21a typhoid vaccines